Scancell lines up its next move after promising vaccine data

Scancell Holdings PLC reported promising preliminary data from its iSCIB1+ melanoma vaccine SCOPE trial, highlighting strong progression-free survival (22 months in Cohort 1, 80.8% at 11 months in Cohort 3) and high objective response rates (69%). The company is now preparing for a pivotal, randomized trial of its off-the-shelf DNA vaccine, engaging with US, European, and UK regulators for a design decision by year-end 2025, with potential trial initiation mid-2026 contingent on funding or partnership. While current cash supports operations into H2 2026, a large-scale trial will necessitate significant additional capital or a strategic partner. Panmure Liberum maintains a 'buy' rating, citing clear clinical progress, discounted risk, and advancements in other pipeline assets like Modi-1 and the GlyMab spin-out.

Analysis

Scancell Holdings PLC is transitioning from a clinical development stage to preparing for a pivotal, registrational trial for its iSCIB1+ melanoma vaccine, driven by highly encouraging data from its SCOPE study. The results demonstrated a strong clinical profile, with a 69% objective response rate across cohorts and a progression-free survival of 22 months in one cohort. Notably, Cohort 3, which combined iSCIB1+ with Bristol Myers Squibb's immunotherapy, showed a progression-free survival rate of 80.8% at 11 months, all with a clean safety profile. The key strategic advantage is its 'off-the-shelf' nature, which promises lower costs and faster production compared to personalized vaccines. The company is now in discussions with US, European, and UK regulators to finalize the design for a large-scale (>450 patient) trial, with a decision anticipated by the end of 2025 and a potential start in mid-2026. However, this progress is contingent on securing substantial funding or a strategic partner, as current cash reserves of £16.9 million are projected to last only into H2 2026, well short of the capital required for a pivotal study. To mitigate single-asset risk, Scancell is advancing its Modi-1 vaccine, with interim data expected in Q3 2025, and is planning to spin out its GlyMab antibody platform, which has already attracted licensing deals from Genmab. Despite the financial overhang and a £15 million operating loss, house broker Panmure Liberum maintains a 'buy' rating and a 32p price target, suggesting the market has heavily discounted the inherent execution and financing risks.

Key Decisions for Investors

• Investors should consider the high-risk, high-reward profile of Scancell, where the promising clinical data and unique 'off-the-shelf' vaccine platform present significant upside, but this is counterbalanced by a critical funding dependency for its upcoming pivotal trial.
• Monitor for key near-term catalysts that could de-risk the company's outlook, specifically any announcement of a strategic partnership for iSCIB1+, the final pivotal trial design feedback from regulators expected by year-end 2025, and interim data readouts from the Modi-1 cancer vaccine trial.
• The current cash position provides a runway only into the second half of 2026, therefore any decision to initiate or add to a position must factor in the high probability of a dilutive capital raise or the announcement of a partnership deal as a prerequisite for the pivotal trial to commence.